The anti-epidermal growth factor receptor (anti-EGFR) antibody cetuximab is clinically approved for the treatment of EGFRexpressing metastatic colorectal cancer and advanced head and neck cancer. Overexpression of EGFR has also been found in more than 70% of carcinomas of the cervix. The overall goal of this study was to determine whether 64 Cu-1,4,7,10-tetraazacyclododecane-N,N9,N$,N9$-tetraacetic acid (DOTA)-cetuximab has potential as an agent for measuring EGFR concentration by PET imaging in cervical cancer tumors. Methods: Cetuximab was conjugated to the bifunctional chelator DOTA and labeled with 64 Cu. EGFR messenger RNA (mRNA) expression was correlated with EGFR densities on the cell surface of 5 different cervical cancer cell lines and with receptor function, measured by internalization of 64 Cu-DOTA-cetuximab. Imaging in tumorbearing mice with small-animal PET was performed using the highest-expressing cervical cancer cell line. Results: The affinity of 64 Cu-DOTA-cetuximab binding for the EGFR was similar in 4 EGFR-positive lines, varying from 0.1 to 0.7 nM. The mRNA expression corresponded well with EGFR densities and levels of internalization, with responses decreasing in the order of CaSki . ME-180 . DoTc2 4510 . HeLa . C-33A. Biodistribution and small-animal PET studies with 64 Cu-DOTA-cetuximab in CaSki tumor-bearing nude mice showed relatively high tumor uptake at 24 h after injection (13.2 6 1.2 percentage of injected activity per gram), although there was also significant retention of activity in the blood and liver accumulation. Conclusion: 64 Cu-DOTA-cetuximab was successfully used to detect and quantify EGFR expression in cervical cancer tumors, and small-animal PET/CT of EGFR-expressing CaSki tumors suggests potential for PET/CT of EGFR-positive tumors.
Cervi cal cancer is the most common gynecologic cancer worldwide. In the United States in 2004, more than 10,500 women were diagnosed and 3,900 died (1) . Although the majority of women present with early-stage disease and are treated successfully with surgery or radiation, 25% of women present with advanced disease. Current treatment for locally advanced cervical cancer consists of cisplatin-based chemotherapy and concurrent radiation. Overall survival rates with this treatment are low, approximately 52% at 5 y (2).
The epidermal growth factor receptor (EGFR) is a member of the pro-survival ErbB family of receptors. Increased expression of EGFR is the hallmark of many human tumors such as cervical cancer, breast cancer, squamous cell carcinoma of the head and neck, and prostate cancer (3, 4) .
The role of EGFR in the tumorigenesis of cervical cancer has been debated over the last decade. In one study, overexpression of EGFR was found in 72.5% of patients with invasive cervical cancer and in 25% of patients with cervical intraepithelial neoplasia (5) . Larger tumors had significantly higher receptor levels, suggesting that EGFR may play a role in malignant transformation. However, 2 subsequent reports suggested that EGFR is not related to the prognosis of cervical cancer (6) or that the EGFR may be downregulated in most cases of cervical cancer (7) . In the latter study, only 10% of tumors showed overexpression of EGFR, compared with normal cervical epithelium. More recent studies have established the role of EGFR overexpression as a predictor of poor prognosis in cervical cancer (8) and have associated EGFR with a poorer prognosis of disease-free and overall survival (9) . Coexpression of EGFR and COX-2 was also found to be a potent molecular risk factor in carcinomas of the cervix (10) .
The fraction of cervical cancers overexpressing EGFR is presently 54%-74% (3). Thus, pharmaceuticals targeting EGFR could provide options for diagnostic tools and treatment, at least in certain subtypes of cervical carcinomas. Cetuximab was the first monoclonal antibody targeted against the ligand-binding site of EGFR to be approved by the Food and Drug Administration for the treatment of patients with EGFR-expressing, metastatic colorectal carcinoma. We, therefore, sought to investigate the use of cetuximab for targeting the EGFR in cervical cancer.
We conjugated cetuximab with the bifunctional chelator 1,4,7,10-tetraazacyclododecane-N,N9,N$,N9$-tetraacetic acid (DOTA) and radiolabeled DOTA-cetuximab with 64 Cu. In this study, we compare EGFR messenger RNA (mRNA) levels with cell-surface EGFR expression and receptor internalization, measured using 64 Cu-DOTA-cetuximab, in several cervical cancer cell lines. We report that EGFR gene expression correlated with cell-surface EGFR expression and with the extent of uptake of 64 Cu-DOTA-cetuximab into tumor cells. We further show that 64 Cu-DOTA-cetuximab is an effective PET agent in tumors expressing high levels of EGFR. These data suggest that 64 Cu-DOTA-cetuximab may be useful for quantifying EGFR expression in tumors by PET.
MATERIALS AND METHODS

Materials
DOTA-mono-N-hydroxysuccinimide ester (DOTA-mono-NHS ester) was purchased from Macrocyclics. Centricon 100 concentrators were purchased from Amicon Inc. All other chemicals were purchased from Aldrich Chemical Co. All buffers were prepared using distilled deionized water (resistivity, ;18 MV) (Milli-Q; Millipore). Cetuximab was kindly provided by ImClone Systems Inc. Female severe combined immunodeficiency (SCID) mice were purchased from Charles River. A cell disrupter (Sonifier; Branson), tissue homogenizer (Tekmar), and centrifuge (RC2-B; Sorvall) were used in receptor-binding experiments. Size-exclusion highperformance liquid chromatography (HPLC) used in conjugation and purification of radiolabeled conjugate was accomplished on an HR 10/300 column (Superose 12; Amersham Biosciences) with a 2487 dual l absorbance detector (Waters) and a radioactive detector (Ortec, model 661; EG&G Instruments). The mobile phase consisted of 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid and 150 mM sodium chloride, pH 7.3, eluted at a flow rate of 0.5 mL/min. Millenium 32 software (Waters) was used to quantify chromatograms by integration. An 8000 automated welltype g-counter (Beckman) was used to measure the activity of sizeexclusion HPLC fractions of animal biodistribution samples and for internalization samples. Levels of radioactivity higher than 0.037 MBq (1 mCi) during radiosynthesis were assayed in a dose calibrator (model-15R; Capintec; Ramsey, NJ). MultiScreen 96-well microtiter plates (Millipore) for receptor-binding assays were measured on a 1450 Microbeta Trilux Liquid Scintillation and Luminescence Counter (PerkinElmer Life Sciences). 64 Cu was produced on a biomedical cyclotron CS-15 at Washington University School of Medicine, as previously reported (11) .
Cell Culture
CaSki and HeLa cell lines were purchased from American Type Culture Collection, and DoTc2 4510, C-33A, and ME-180 cell lines were provided by F. Patrick Ross, Washington University School of Medicine. Cell culture medium was purchased from Gibco, fetal bovine serum (FBS) from Hyclone, and all other medium supplements from the Washington University School of Medicine Tissue Culture Support Center. C-33A and HeLa cells were maintained in Eagle's minimum essential medium (EMEM) in Earle's balanced salt solution and 2 mM L-glutamine modified to contain 1.5 g of sodium bicarbonate per liter, supplemented with 1 mM nonessential amino acids, 10 mM sodium pyruvate, and 10% FBS. CaSki cells were maintained in RPMI 1640 medium with 2 mM L-glutamine modified to contain 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 1 mM sodium pyruvate, 4.5 g of glucose per liter, and 1.5 g of sodium bicarbonate per liter, supplemented with 10% FBS. DoTc2 4510 cells were maintained in Dulbecco's modified Eagle's medium with 4 mM L-glutamine modified to contain 4.5 g of glucose per liter and 1.5 g of sodium bicarbonate per liter, supplemented with 10% FBS. ME-180 cells were maintained in McCoy's 5a medium with 1.5 mM L-glutamine and 2.2 g of sodium bicarbonate per liter, supplemented with 10% FBS.
EGFR Gene Expression
In the context of a parallel study designed to perform molecular profiling on cervical cancer cell lines, 2 mcg of cellular RNA were analyzed on U133Plus2 gene expression microarrays (Affymetrix) using standard protocols provided by the manufacturer. Biotinylated target preparation, array hybridization, and scanning were performed by the Siteman Cancer Center Multiplexed Gene Analysis Core facility. From the microarray dataset of 23 cell line samples, probe set data for the EGFR transcript (4 independent probe sets) were extracted, normalized across all arrays in the experiment, and used to compare relative transcript abundance of EGFR.
Preparation of 64 Cu-DOTA-Cetuximab
DOTAwas conjugated to cetuximab in 0.1 M disodium phosphate (Na 2 HPO 4 ) (pH 7.5) using an adaptation of the method described by Lewis et al. (12) . Cetuximab (2 mg/mL) was washed with 0.1 M Na 2 HPO 4 (pH 7.5) using a YM-100 centrifugal filter device (Centricon) and then concentrated. DOTA-mono-NHS ester was dissolved in 0.1 M Na 2 HPO 4 (pH 7.4), and pH was adjusted to 7.4 by adding 0.1 M sodium hydroxide. An aliquot of this solution was added to the concentrated cetuximab in a 120:1 molar ratio of DOTA-mono-NHS ester to cetuximab and followed by incubation at 4°C overnight with end-over-end rotation. The conjugate was then transferred to a Centricon YM-100, diluted to 2.0 mL with 0.1 M ammonium citrate (pH 5.5), and centrifuged. This procedure was repeated to remove small-molecule reactants, and the conjugate was collected from the membrane. Purity and concentration of the resulting DOTA-cetuximab conjugate were determined by sizeexclusion HPLC. Titration of DOTA-cetuximab with nat Cu-copper acetate spiked with 64 Cu using a previously published method (13) revealed that the ratio of DOTA to cetuximab achieved by this procedure was 5:5.
Radiolabeling of DOTA-cetuximab with 64 Cu was performed by adding approximately 100 mg of the conjugate to 19-74 MBq (0.5-2 mCi) of 64 CuCl 2 in 0.1 M ammonium citrate buffer, pH 5.5, followed by a 1-h incubation at 40°C. The radiochemical purity of the resulting 64 Cu-DOTA-cetuximab was determined by sizeexclusion HPLC and radio-thin-layer chromatography. If necessary, 64 Cu-DOTA-cetuximab was challenged with 10 mM ethylenediamine tetraacetic acid (5 mL) to complex-free 64 Cu. 64 Cu-DOTAcetuximab was then isolated with a desalt spin column (0.5 mL) (Zeba; Pierce) to obtain radiochemical purities greater than 95%. Specific activity of the final product was 0.93 GBq/mg (25 mCi/mg).
A previous study reported the synthesis of 64 Cu-DOTA-cetuximab with a specific activity of 1.24 GBq/mg, with 21.5 DOTA residues per cetuximab (14) .
Receptor Binding of 64 Cu-DOTA-Cetuximab
Assays were performed with live cells using a modification of a previously described method (15) . 64 Cu-DOTA-cetuximab (0.05-10 nM) was incubated with cell monolayers of the 5 cervical cancer cell lines in 24-well plates for 2 h at 4°C in their respective growth media. CaSki, ME-180, and DoTc2 4510 cells contained 1 · 10 5 cells/well (525 cells/mm 2 ); HeLa cells contained 5 · 10 4 cells/well (260 cells/mm 2 ); and C-33A cells contained 1.5 · 10 5 cells/well (790 cells/mm 2 ). The cells were washed twice with 1 mL of ice-cold Hanks' balanced salt solution and lysed by incubation at 90°C in 0.9 mL of 0.1 M sodium hydroxide for 30 min. Aliquots of each sample were analyzed for protein by a bicinchoninic acid assay. Samples were transferred into microfuge tubes and counted in a g-counter.
Nonspecific binding was determined in parallel assays containing an excess (200 nM) of unlabeled cetuximab. Specific binding was obtained by subtracting nonspecific binding from total binding and was corrected for total protein content. Dissociation constants in nM and maximum receptor densities (B max ) in fmol/mg were estimated by nonlinear fitting of the specific binding versus the concentration of 64 Cu-DOTA-cetuximab using Prism software (GraphPad).
Internalization of 64 Cu-DOTA-Cetuximab
Cells (approximately 5 · 10 5 /well) were seeded in 6-well plates containing their respective growth medium and were incubated at 37°C in 5% CO 2 , until 80% confluent. On the day of the assay, the medium was aspirated and replaced with 3 mL of fresh growth medium. For determination of unspecific internalization of 64 Cu-DOTA-cetuximab, 1 set of wells was incubated with unlabeled cetuximab (1,000-fold excess) at 37°C in 5% CO 2 for 10 min to block receptors. 64 Cu-DOTA-cetuximab (133.2 kBq [3.6 mCi], 0.38 mg/15 mL) was added and incubated at 37°C in 5% CO 2 for various time points, after which the radioactive medium was aspirated and the plate was washed twice with 2 mL of phosphatebuffered saline (PBS). To collect the surface-bound fraction of this receptor-mediated process, each well was treated with 20 mM sodium acetate in PBS (pH 3.0) and was incubated at 4°C for 10 min and then followed by a second wash with 20 mM sodium acetate in PBS (pH 3.0) without incubation, which was pooled with the first rinse. The cellular fraction was dissolved with 0.5% sodium dodecyl sulfate in PBS. All of the fractions were counted for radioactivity with a g-counter. The percentage internalized was the amount of activity in the final cell pellet, corrected for activity in the blocked fractions and background activity and normalized to protein content.
Tumor Xenografts
CaSki tumors were grown in female SCID mice by following a modification of the protocol of Cairns and Hill (16) . Cells (5 · 10 6 ) were implanted subcutaneously in the flank, and palpable tumors were observed 3-4 wk after implantation.
In Vivo Biodistribution and Small-Animal PET Imaging
Animal studies were conducted in accordance with the highest standards of care as outlined in the National Institutes of Health Guide for Care and Use of Laboratory Animals (17) and the policy and procedures for animal research at Washington University School of Medicine. After injection of aliquots of 64 Cu-DOTAcetuximab (100 mL, 555 kBq [15 mCi]) via the tail vein, blood,
For imaging studies, mice bearing CaSki tumors were anesthetized by inhalation of 2% isoflurane, injected with 64 Cu-DOTAcetuximab (7,400 kBq [200 mCi], 20 mg), and scanned at 24 h after injection on a small-animal PET device (Focus, model 120 or 220; Concorde Microsystems Inc.). High-resolution coregistration micro-CT imaging was performed to monitor tumor volume and morphology at 24 h after injection. All small-animal PET images were reconstructed, and regional tracer concentrations were quantified by use of the ASIPRO software package (Concorde Microsystems Inc.). Quantitative data were expressed as standardized uptake values, which are defined as the counts per second per pixel in a region of interest encompassing the entire organ divided by total counts per second per pixel in the mouse. (Fig. 1) . Cell lines were classified according to their level of EGFR expression from the averaged probe set signals. In addition, cDNA templates from each of the cell lines were used to perform double-stranded resequencing of the entire EGFR coding region. None of the cell lines demonstrated previously characterized sequence alterations either within or external to the EGFR coding domain (data not shown).
RESULTS
Twenty
Five cervical cancer cell lines, covering the entire range of EGFR mRNA expression, were selected for further study: CaSki (high EGFR expression), ME-180 and DoTc2 4510 (both midrange EGFR expression), HeLa (low EGFR expression), and C-33A (negative for EGFR expression).
To determine the relationship between EGFR gene expression levels and cell-surface expression of the EGFR, saturation receptor binding of 64 Cu-DOTA-cetuximab to the EGFR was performed. Binding studies were performed in live cells at 4°C to inhibit internalization and trafficking of cetuximab. The results are shown in Figure 2 .
In Figure 2 , 4 of the 5 cell lines exhibited saturable 64 Cu-DOTA-cetuximab binding. The fifth line, C-33A, showed no specific 64 Cu-DOTA-cetuximab binding. The affinity of 64 Cu-DOTA-cetuximab binding for the EGFR was similar in the 4 EGFR-positive lines, varying from 0.1 to 0.7 nM. These values are consistent with those reported for the binding of unmodified cetuximab to the EGFR (dissociation constant, 0.1-0.4 nM) (18) . Therefore, conjugation to DOTA and complexation with 64 Cu did not affect the affinity of cetuximab toward its antigen. The B max for 64 Cu-DOTAcetuximab binding to these cell lines paralleled the levels of EGFR expression determined by microarray analysis ( Fig. 2 ; Table 1 ).
Internalization assays were next performed to determine whether EGFR number correlated with increased uptake of 64 Cu-DOTA-cetuximab by receptor-mediated endocytosis. For these experiments, cells were incubated with 64 Cu-DOTA-cetuximab at 37°C, and internalization was measured by determining the amount of cell-associated 64 Cu-DOTAcetuximab that was stable to acid wash (PBS) supplemented with 20 mM sodium acetate, pH 3.0. The data in Figure 3A show that all EGFR-positive cell lines internalized 64 Cu-DOTA-cetuximab. Internalization was linear for the first 15-30 min but began to plateau after approximately 1 h. No uptake was observed in the EGFR-negative C-33A cells. The maximum level of internalization observed after 4 h paralleled receptor expression levels as determined by 64 Cu-DOTA-cetuximab saturation binding (Table 1) .
To determine whether the difference in uptake was because of an increase in the rate of internalization, 64 Cu-DOTA-cetuximab uptake was followed over a 15-min time course, and the data were plotted as the ratio of internalized 64 Cu-DOTA-cetuximab to cell-surface 64 Cu-DOTA-cetuximab versus time. This normalizes uptake to receptor number and allows assessment of the rate of internalization on a perreceptor basis. Figure 3B shows that the slopes of the InSur plots were similar for all 4 EGFR-positive cell lines, indicating that the rate of uptake was similar in all lines. Thus, the difference in the absolute amount of 64 Cu-DOTA-cetuximab internalized can be attributed to differences in the number of cell-surface EGFRs.
In CaSki cells, the line that expressed the highest level of EGFRs, approximately 50,000 fmol of 64 Cu-DOTAcetuximab per milligram were internalized within 4 h. This corresponds to an internalized 64 Cu-DOTA-cetuximab-to- receptor ratio of 24 (Table 1 ). This correspondence suggests that the EGFRs are continuously recycled to the cell surface rather than being targeted into the degradation pathway. The ratio of internalized 64 Cu-DOTA-cetuximab to EGFR number was similar for the ME-180 (28), DoTc2 4510 (25) , and HeLa (20) cells, indicating that all lines exhibited the same phenomenon of receptor recycling followed by cetuximab-induced receptor internalization.
To assess the interaction of 64 Cu-DOTA-cetuximab with cervical cancer cells in vivo, 5 · 10 6 CaSki cells were injected into female SCID mice. Three weeks later, palpable tumors were observed. 64 Cu-DOTA-cetuximab was then injected into these tumor-bearing athymic nude mice (n 5 5), and its biodistribution was assessed 24 h after injection (Fig. 4) . Uptake into the cervical cancer cell tumor was high (13.2 6 1.2 %ID/g). By contrast, uptake was low in muscle (3.4 6 0.2 %ID/g) and bone (2.6 6 0.2 %ID/g). However, uptake in other nontarget organs remained high at 24 h, especially in the blood (23.8 6 0.9 %ID/g) and the spleen (25.6 6 1.7 %ID/g). This biodistribution at 24 h indicates that optimal contrast is likely observed at time points greater than 24 h after injection, which is consistent with data from Cai et al. (14) and data from our group (15) .
A preliminary small-animal PETCT experiment was performed in a CaSki tumor-bearing mouse that showed high 64 Cu-DOTA-cetuximab uptake in the tumor mass but relatively low nontarget uptake 24 h after injection (Fig. 5) . The specific uptake value for the tumor was 1.39, whereas the values for the liver and heart were 1.72 and 1.63, respectively. These data are consistent with the biodistribution data, indicating relatively high liver and blood accumulation, although the tumor is visible at 24 h.
DISCUSSION
Despite widespread screening for cervical cancer, this disease continues to claim lives, particularly among medically underserved populations of women. Gardasil (Merck & Co., Inc.), a recombinant vaccine against human papilloma virus types 6, 11, 16, and 18, was approved by the Food and Drug Administration in 2006 and by the European Union in 2007. Although this is an important step in the battle against cervical cancer, the viral types for which this vaccine provides protection are responsible for only 70% of the cases of cervical cancer. Also, the vaccine will provide no protection for women who have already been exposed to the target strains (19) . Therefore, the need for advances in the diagnosis and treatment of cervical cancer will persist.
Cetuximab has been approved in Europe and the United States for the clinical treatment of advanced metastatic colorectal cancer and advanced head and neck cancer. Like cervical cancer, these tumors are known to express elevated levels of EGFRs (20, 21) . The studies presented here were aimed at investigating the use of cetuximab in the diagnosis and subtyping of cervical cancers. Microarray analysis of 23 human cervical cancer cell lines demonstrated significant differences among lines in the level of expression of EGFR mRNA. Thus, the sensitivity of these tumors to cetuximab-induced cell killing is likely to be highly variable. In particular, tumors that do not express EGFRs are not likely to be effectively targeted by cetuximab.
To determine the potential use of cetuximab in identifying EGFR-positive cell lines, we conjugated cetuximab with DOTA and radiolabeled it with 64 Cu. This radionuclide (half life, 12.7 h; b 1 , 17.4%; b 2 , 41%) emits both b 1 and b 2 radiation, allowing for the use of 64 Cu radiopharmaceuticals with high tumor-to-background ratios for both PET imaging and targeted radiotherapy of cancer.
We used 64 Cu-DOTA-cetuximab to quantify EGFR levels and found that the expression of EGFR mRNA correlated with the number of cell-surface EGFR in 5 human cervical cancer cell lines. In addition, the degree of 64 Cu-DOTAcetuximab internalization correlated with both EGFR mRNA and protein levels. CaSki cells, which showed the highest EGFR mRNA levels by microarray analysis, were also found to have the highest maximum density of EGFR per milligram of protein. In addition, they internalized more 64 Cu-DOTAcetuximab than did the other cell lines. At the other end of the spectrum, C-33A cells responded negatively to all oligonucleotide probe sets, and no EGFR could be detected by 64 Cu-DOTA-cetuximab-binding assays. Thus, 64 Cu-DOTAcetuximab binding appears to be a useful probe for quantifying EGFR number and function.
Several recent reports have investigated whether the response of colorectal tumors to cetuximab therapy is correlated with EGFR mRNA copy number or EGFR protein levels. Moroni et al. (21) demonstrated a correlation between response to cetuximab and increased EGFR gene copy number in patients with metastatic colorectal cancer. By contrast, Vallböhmer et al. (22) failed to find a significant correlation between colorectal tumor EGFR mRNA levels and patient response to cetuximab, but this study was hampered by a small sample size. Nonetheless, it was observed that patients with higher levels of gene expression of the EGFR had a shorter overall survival. Despite these correlations, 1 study of patients with colorectal cancer with no detectable tumor levels of EGFR as determined by immunohistochemistry showed that approximately 25% of these patients respond to cetuximab (23) . The data presented in these studies suggest that the quantification of EGFR by immunohistochemistry is unreliable and demonstrate the need for a more sensitive method for measuring EGFR for use in stratifying patients for potential response to cetuximab. Molecular imaging of EGFR with PET/CT and cetuximab labeled with a positron emitter, compared with traditional methods, may be a sensitive alternative measure of EGFR.
To assess the potential for 64 Cu-DOTA-cetuximab as a PET/CT agent, a preliminary study was performed in which 64 Cu-DOTA-cetuximab was injected into nude mice bearing tumors derived from CaSki cervical cancer cells. Biodistribution analysis demonstrated high uptake of 64 Cu-DOTAcetuximab in implanted CaSki tumors at 24 h after injection (13.2 6 1.2 %ID/g). This result is comparable to the highest level of uptake of 64 Cu-DOTA-cetuximab in a recent study of 7 tumor cell lines implanted in athymic nude mice (14) . The uptake in the liver was comparable in both studies (14.0 6 1.4 %ID/g at 16 h after injection vs. 15.5 6 0.5 %ID/g at 24 h after injection in our study), but retention of radiopharmaceutical in the blood was significantly higher in our system (14) . Copper can dissociate from the chelator DOTA, which may in part account for the observed uptake in nontarget organs. The use of bifunctional chelators that form more stable copper complexes, such as 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane (CB-TE2A), can alleviate copper dissociation and reduce nonspecific copper uptake (24) . However, CB-TE2A is labeled with 64 Cu at 95°C and a pH greater than 8 (25) . Antibodies are denatured under these conditions, and until suitable prelabeling procedures for 64 Cu-CB-TE2A with subsequent conjugation to antibodies are available, it will be necessary to use chelators that can be radiolabeled under milder conditions. At any rate, that uptake of 64 Cu-DOTA-cetuximab into CaSki tumors was readily detected in our studies and that its extent of uptake correlates with EGFR number suggests that further examination of this radiopharmaceutical with additional time points with the CaSki model, as well as imaging of EGFRs in other cervical cancer mouse models, is warranted.
CONCLUSION
We demonstrated that the expression of EGFR mRNA correlated well with protein levels of EGFR as determined by 64 Cu-DOTA-cetuximab. In addition, the levels of internalization of 64 Cu-DOTA-cetuximab in the 5 cervical cancer cell lines corresponded to the EGFR density, and the rates of internalization were similar. As several studies have demonstrated that EGFR densities in tumors do not typically correlate with response to cetuximab therapy, questions arise as to whether determination of EGFR concentration in tumors with 64 Cu-DOTA-cetuximab and PET would be a more valuable tool than immunohistochemistry and less invasive than tumor biopsy followed by mRNA analysis. Data presented here strongly suggest that 64 Cu-DOTAcetuximab is an accurate biomarker of EGFR expression levels, and this agent with PET might be useful for patient selection and therapeutic monitoring with all types of EGFR inhibitors, including small-molecule and antibody-based, although further imaging studies are warranted.
